A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
作者:Gloria Hernández-Torres、Mariateresa Cipriano、Erika Hedén、Emmelie Björklund、Ángeles Canales、Debora Zian、Ana Feliú、Miriam Mecha、Carmen Guaza、Christopher J. Fowler、Silvia Ortega-Gutiérrez、María L. López-Rodríguez
DOI:10.1002/anie.201407807
日期:2014.12.8
of MAGL inhibitors are needed to validate this enzyme as a therapeutic target. Here we report a potent, selective, and reversible MAGL inhibitor (IC50=0.18 μM) which is active in vivo and ameliorates the clinical progression of a multiple sclerosis (MS) mouse model without inducing undesirable CB1‐mediated side effects. These results support the interest in MAGL as a target for the treatment of MS
单酰基甘油脂酶(MAGL)是负责内源性大麻素2-花生四烯酸甘油酯(2-AG)失活的酶。MAGL抑制剂在几种疾病模型中均具有镇痛和组织保护作用。然而,迄今为止描述的几种有效且选择性的MAGL抑制剂不可逆地阻断了该酶,并且这可能导致药理学耐受性。因此,还需要其他类别的MAGL抑制剂来验证该酶是否可作为治疗靶标。此处我们报告一个有效的,选择性,和可逆的抑制剂MAGL(IC 50 = 0.18μ中号),它是体内活性和改善多发性硬化(MS)的小鼠模型的临床进展,而不引起不希望的CB 1介导的副作用。这些结果支持了对MAGL作为MS治疗靶标的兴趣。